Keryx Biopharmaceuticals (KERX) Highlighted As Today's Perilous Reversal Stock

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified Keryx Biopharmaceuticals ( KERX) as a "perilous reversal" (up big yesterday but down big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified Keryx Biopharmaceuticals as such a stock due to the following factors:

  • KERX has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $24.2 million.
  • KERX has traded 166,904 shares today.
  • KERX is down 3% today.
  • KERX was up 11.9% yesterday.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in KERX with the Ticky from Trade-Ideas. See the FREE profile for KERX NOW at Trade-Ideas

More details on KERX:

Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease in the United States. Currently there are 8 analysts that rate Keryx Biopharmaceuticals a buy, 1 analyst rates it a sell, and none rate it a hold.

The average volume for Keryx Biopharmaceuticals has been 2.5 million shares per day over the past 30 days. Keryx has a market cap of $1.4 billion and is part of the health care sector and drugs industry. The stock has a beta of 6.55 and a short float of 29.5% with 16.47 days to cover. Shares are up 32.8% year-to-date as of the close of trading on Thursday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreetRatings.com Analysis:

TheStreet Quant Ratings rates Keryx Biopharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and poor profit margins.

Highlights from the ratings report include:
  • KERYX BIOPHARMACEUTICALS INC has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. Earnings per share have declined over the last two years. We anticipate that this should continue in the coming year. During the past fiscal year, KERYX BIOPHARMACEUTICALS INC reported poor results of -$0.57 versus -$0.36 in the prior year. For the next year, the market is expecting a contraction of 57.9% in earnings (-$0.90 versus -$0.57).
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 97.3% when compared to the same quarter one year ago, falling from -$11.36 million to -$22.41 million.
  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Biotechnology industry and the overall market, KERYX BIOPHARMACEUTICALS INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • Net operating cash flow has significantly decreased to -$17.57 million or 140.96% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
  • The gross profit margin for KERYX BIOPHARMACEUTICALS INC is currently extremely low, coming in at 0.00%. KERX has continued with the weak profit margin when compared to the same quarter of last year.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

China Slashes Auto Import Tariffs as Trump's Trade Push Gets Big Early Win

China Slashes Auto Import Tariffs as Trump's Trade Push Gets Big Early Win

Micron Spikes After $10 Billion Buyback Plan Caps Bullish Q3 Earnings Forecast

Micron Spikes After $10 Billion Buyback Plan Caps Bullish Q3 Earnings Forecast

Global Stocks Push Higher as China Tariff Move, Softer US Dollar Boost Sentiment

Global Stocks Push Higher as China Tariff Move, Softer US Dollar Boost Sentiment

Get to Know Stacey Cunningham, the NYSE's First Female Chief in 226 Years

Get to Know Stacey Cunningham, the NYSE's First Female Chief in 226 Years

60 Seconds: What is the Volcker Rule and How Does it Affect Your Portfolio?

60 Seconds: What is the Volcker Rule and How Does it Affect Your Portfolio?